Advertisement
The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share
U.S. Centers for Disease Control and Prevention • Medical News

Potential AIDS Preventive Doubles as a Contraceptive

November 13, 2002


This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

A Johns Hopkins University team has devised a microbicide that not only prevents STDs such as AIDS but also acts as a contraceptive. The mechanism of the odorless ointment, called BufferGel, is based on simple chemistry: Alkaline compounds neutralize acid -- and other chemicals can reverse that process. The vaginal area is mildly acidic, with a pH level of four (neutral is seven), comparable to the acidity of wine. "That degree of acidity kills sperm, and all sorts of germs," said Richard Cone, a biophysicist at Hopkins who helped develop BufferGel.

Semen, with a pH between seven and eight, raises the vaginal pH to seven for hours. This allows sperm to survive long enough to fertilize an egg, but enables germs to infect cells. Based on this effect, researchers devised a strategy that mimics the vagina's natural defenses. Researchers found a pharmaceutical compound used to thicken ointments was able to preserve vaginal acidity even in the presence of sperm, so they made it into a lubricant gel. "We wanted to use something that had a long track record of safety with no side effects," said Dr. Thomas Moench, a co-developer of the gel.

Initial tests, conducted in the early '90s, indicated BufferGel preserved the acidity of the vagina, killing such STDs as HIV, gonorrhea, chlamydia, herpes, syphilis, HPV and trichomoniasis, the most common STD. Safety studies on 125 women in the United States and abroad were recently completed. A contraceptive trial by the National Institutes of Health is underway in which 975 women will use a diaphragm with either BufferGel or a conventional spermicide. If all goes well, BufferGel could hit US markets in two years.

The more crucial test, say researchers, will begin in the spring, when 8,500 women in the United States, India and Africa will see if BufferGel can thwart HIV. If it is effective, it will provide an alternative to women whose partners refuse to use condoms. "This puts the control back into a woman's hands," said Cone.

Back to other CDC news for November 13, 2002

Previous Updates
 | Search the CDC archive


This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Adapted from:
Los Angeles Times
11.11.02; Linda Marsa

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share

See Also
Read More About News & Research

 

Advertisement